#4610 LACK OF EFFICACY AND SAFETY OF ECULIZUMAB FOR TREATMENT OF ANTIBODY-MEDIATED REJECTION FOLLOWING RENAL TRANSPLANTATION

Abstract Background and Aims We evaluated the efficacy safety of eculizumab in comparison with plasmapheresis intravenous immunoglobulin therapy renal transplant recipients diagnosed antibody-mediated rejection (AMR). Method This was a multicenter, open-label, prospective, randomized analysis. The patients were by type (eg, infusions or standard care [SOC]: plasmapheresis/intravenous immunoglobulin). (ie, arm: 7 patients, SOC 4 patients) for continued presence donor-specific antibodies (DSAs) C4d (staining on biopsy), as well histologic evidence, using repeat biopsy after treatment. Results allograft biopsies revealed that did not prevent progression to glomerulopathy. Cases AMR early post-transplantation period 2 (eculizumab 1 patient, patient) late 9 patients. Most reports show eculizumab, combination other therapeutic measures such PP and/or IVIG, effectively reversed rejection. However, alone could treat effectively. Only arm experienced reversal, no graft losses occurred either group. After treatment, DSA titers generally decreased compared taken at time diagnosis. There serious adverse effects arm. Conclusion Eculizumab cannot does acute from progressing chronic it should be considered potential alternative because may associated levels.